Our country's scientists have discovered that a migraine drug may help in immunotherapy for triple-negative breast cancer.

Triple-negative breast cancer accounts for 15% to 20% of all breast cancer patients, characterized by high malignancy, low survival rate, and easy recurrence and metastasis within 5 years. The Breast Tumor Center of Fudan University Affiliated Tumor Hospital, in collaboration with the research team at Fudan University Institute of Brain Science and Translation Research, discovered that sensory nerves in tumors are the "culprits" that cause some triple-negative breast cancer patients to develop resistance to immunotherapy in the short term, and found that a drug used to treat migraines can enhance sensitivity to immunotherapy. The related findings were published on the 6th in the international academic journal "Cell".